Chronic Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sao Paulo University
Study Contact Backup
- Name: Samuel K Shinjo, PhD
- Phone Number: 55113061-7176
- Email: samuel.shinjo@usp.br
Study Locations
-
-
Sao Paulo
-
São Paulo, Sao Paulo, Brazil
- Recruiting
- Samuel K Shinjo
-
Contact:
- Samuel K Shinjo, PhD
- Phone Number: 551130617176
- Email: samuel.shinjo@usp.br
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Classification criteria - EULAR/ACR 2017
- Classification critera - Connors et al.
Exclusion Criteria:
- Neoplasia
- Using heart pacemarker
- Using visceral metalic clips
- Infections (HIV, HTLV-1, Hepatitis, etc)
- Pregnance
- Previous historical of convulsions or epilepsies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Transcranial direct current stimulation
Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head.
The electrodes will be located of the primary motor cortex.
The electrode with cathode will be positioned at contralateral to the dominant limb and the anode charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb.
The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes.
The stimulation will happen simultaneously to aerobic exercises for 20 minutes.
Total number of stimulation associated with aerobic exercise sessions: 10
|
Chronic transcranial direct current stimulation
|
|
Placebo Comparator: Placebo
This group will not receive a transcranial direct current stimulation session.
However, the patients will do aerobic exercises for 20 minutes.
Total number of sham-stimulation associated with aerobic exercise sessions: 10
|
Chronic transcranial direct current stimulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of treatment-emergent advser events
Time Frame: After 30 minutes of intervention
|
Frequency of disease relapses (based on the questionnaire of secondary outcome measures) and tolerability (patients' symptom registration)
|
After 30 minutes of intervention
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: Before stimulation
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome measures) and tolerability (patients' symptom registration)
|
Before stimulation
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: Immediately after all stimulation section
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome
|
Immediately after all stimulation section
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: After 30 days after last stimulation section
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome
|
After 30 days after last stimulation section
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: After 60 days after last stimulation section
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome
|
After 60 days after last stimulation section
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: After 90 days after last stimulation section
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome
|
After 90 days after last stimulation section
|
|
Frequency of treatment-emergent adverse events [safety and tolerability]
Time Frame: After 300 days after last stimulation section
|
Frequency of disease relapsing (based on the questionnaire of secondary outcome
|
After 300 days after last stimulation section
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myositis Disease Activity Assessment Visual Analogue Scales (MYOACT)
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
This partially validated tool measures the degree of disease activity of extra-muscular organ systems and muscle.
The questionnaire is a series of physician's assessments of disease activity.
Score ranges: 0 (best) - 60 (worst).
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Serum levels of Muscle enzymes
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
This partially validated tool measures the serum activities of at least 2 of the 4 muscle-associated enzymes including creatine phosphokinase (CK), the transaminases (ALT, AST), lactate dehydrogenase (LD) and aldolase.
The reference range value of each muscle enzyme will depend on the laboratory anaysis (kits).
International Unit: U/L.
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Health Assessment Questionnaire (HAQ)
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
Especific questionnaire (health assessment questionnaire).
Pontuaction 0.00 (best) - 3.00 (worst)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Manual Muscle Testing (MMT)
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
This partially validated tool assesses muscle strength using manual muscle testing (MMT).
A 0 - 10 point scale is proposed for use.
An abbreviated group of 8 proximal, distal, and axial muscles performs similarly to a total of 24 muscle groups, and is also proposed for use for research studies.
Pontuaction: 0 (worst) - 80 (best)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Patient Global Activity
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
This partially validated tool measures the global evaluation by the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm.
visual analogue scale.
Pontuaction: 0 (best) - 10 (worst)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Physician Global Activity
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
This partially validated tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm.
visual analogue scale.
Pontuaction: 0 (best) - 10 (worst)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Fatigue Severity Scale
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
The questionnaire offers general fatigue scored by the patients, from 0 (better) to 10 (worse).
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
The questionnaire offers general pain scored by the patients, from 0 (better) to 10 (worse).
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Short Physical Performance Battery (SPPB)
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
The value ranges from 0 to 4 in different aspects of funcionality.
The scores are compared among different periods of intervention (real or sham-stimulation)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
|
Timed up and go test
Time Frame: Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
To determine fall risk and measure the progress of balance, sit to stand and walking (seconds).
The duration will be compared to before versus after intervation (real or sham-stimulation).
Long duration (worse) versus short duration (better)
|
Six times: (a) Before stimulation; (b) Immediately after all stimulation section; (c) after 30, 60, 90 and 300 days after last stimulation section
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Samuel K Shinjo, Brazil
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MYO-HCFMUSP-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.